# Gajus Worthington

> Gajus Worthington is a life sciences entrepreneur, engineer, and inventor who turned an idea for circuits that move fluid instead of electrons into Fluidigm, a microfluidics company he co-founded in 1999 and led as CEO through its IPO and years as a public company. Today he is Chairman and CEO of Superfluid Dx, a South San Francisco company building a blood test that reads cell-free messenger RNA from the brain to diagnose Alzheimer's disease earlier and more precisely. Between those chapters he served as COO of the Chan Zuckerberg Biohub, co-founded Kaizen Therapeutics and the ML/AI healthcare company StatOS, and became a Managing Partner at WRQ Sciences.

- **Role:** Chairman and Chief Executive Officer at Superfluid Dx, Inc.
- **Organizations:** Superfluid Dx, Inc., WRQ Sciences, Kaizen Therapeutics, StatOS, Chan Zuckerberg Biohub, Fluidigm Corporation (now Standard BioTools), Actel Corporation
- **Nationality:** American
- **Education:** B.S. in Physics, Stanford University, M.S. in Electrical Engineering, Stanford University
- **Known for:** Co-founded Fluidigm and led it as CEO for 17 years, from inception through a public-company IPO., Pioneered the commercialization of microfluidic large-scale integration - integrated circuits that route fluids instead of electrons., Took Fluidigm public in 2011, raising roughly $75 million after a failed 2008 attempt.

## Career timeline

- **1994** — Joined Actel Corporation, a public semiconductor company, holding staff and management roles through 1999, becoming Director of Strategic Marketing and Product Planning.
- **1999** — Co-founded the company (originally Mycometrix) with Stanford and Caltech scientist Steve Quake to commercialize microfluidic large-scale integration; served as President, CEO, and Director.
- **2001** — Company renamed Fluidigm Corporation.
- **2008** — Navigated an ill-timed, failed IPO attempt during the financial crisis.
- **2011** — Led Fluidigm to a successful IPO, raising about $75 million.
- **2016** — Stepped down as CEO of Fluidigm after 17 years.
- **2016** — Joined the Chan Zuckerberg Biohub as Chief Operating Officer, serving nearly five years.
- **2023** — Became Chairman and CEO of Superfluid Dx (formed from Molecular Stethoscope) after WRQ Sciences led an oversubscribed Series A; also a Managing Partner at WRQ Sciences.

## Achievements

- Co-founded Fluidigm and led it as CEO for 17 years, from inception through a public-company IPO.
- Pioneered the commercialization of microfluidic large-scale integration - integrated circuits that route fluids instead of electrons.
- Took Fluidigm public in 2011, raising roughly $75 million after a failed 2008 attempt.
- Served as COO of the Chan Zuckerberg Biohub, helping build and scale the organization for nearly five years.
- Co-founded Kaizen Therapeutics (broad-spectrum antivirals) and StatOS (ML/AI healthcare).
- Elected member of the American Institute for Medical and Biological Engineering.
- Holder of patents as an inventor in microfluidics.

## Latest updates

- **2023-09** — WRQ Sciences and Superfluid Dx announced completion of an oversubscribed Series A financing, with WRQ acquiring majority ownership of Molecular Stethoscope, now operating as Superfluid Diagnostics.
- **2023-12** — Listed as having last raised funding around December 2023; serving as Chairman and CEO of Superfluid Dx in South San Francisco.

## Links

- Website: https://superfluiddx.com
- LinkedIn: http://www.linkedin.com/in/gajus-worthington-8454a535
- YouTube: https://www.youtube.com/watch?v=HhwB8MtgnN8

---

Profile page: https://yespress.io/gajus-worthington
Published by YesPress — https://yespress.io
Last updated: 2026-06-12